Kyorin Pharmaceutical Co. et al., 2017-04-20: The Japanese phase III registration for the trial that became the Zymso approval: 90 patients planned, multicentre randomised double-blind placebo-controlled, first enrolment 25 May 2017, completed, with results available and linked to the 2021 publication.
Results available: Yes
Results field of the registry record
Kyorin Pharmaceutical Co. et al., 2017-04-20: The Japanese phase III registration for the trial that became the Zymso approval: 90 patients planned, multicentre randomised double-blind placebo-controlled, first enrolment 25 May 2017, completed, with results available and linked to the 2021 publication. C9/C5 Japanese registry record. Record fields: phase 3; target sample size 90; sponsor Kyorin Pharmaceutical; intervention KRP-116D (INN dimethyl sulfoxide), 50 mL intravesical once every two weeks against placebo; primary outcome O'Leary and Sant's IC symptom index; secondary ID JapicCTI-173566; date of completion 18/01/2021 (as printed); results URL https://pubmed.ncbi.nlm.nih.gov/33580603/. Country: Japan. Comparator: placebo. Results posted.
